Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is associated with favorable long-term survival in EGFR mutation-positive NSCLC, even in patients with advanced disease and poor overall condition, as in the present case. This evidence concerns the gene EGFR and non-small cell lung carcinoma.